Polio vaccine attenuated vaccine strains. In 1958, the National Institutes of Health created a special committee on live polio vaccines. The various vaccines were carefully evaluated for their ability to induce immunity to polio, while retaining a low incidence of neuropathogenicity in monkeys. Large-scale clinical trials performed in the Soviet Union in late 1950s to early 1960s by Mikhail Chumakov and his colleagues demonstrated safety and high efficacy of the vaccine. Based on these results, the Sabin strains were chosen for worldwide distribution. Fifty-seven nucleotide substitutions distinguish the attenuated Sabin 1 strain from its virulent parent (the Mahoney serotype), two nucleotide substitutions
Brian Hanley (microbiologist) Brian Hanley (microbiologist) Brian Hanley (born c. 1957) is an American microbiologist and founder of Butterfly Sciences. He is known for using an experimental gene therapy to try to improve health span, and is the first subject in the study. Hanley was 60 years old as of February 2017 and holds a PhD in Microbiology from University of California, Davis. In 2009 he founded Butterfly Sciences in Davis, California to develop a gene therapy to treat HIV AIDS using a combination of GHRH and an intracellular vaccine. He has numerous articles and blog posts, and academic publications in epidemiology, biotechnology,